MTVAHealthcare · Biotechnology

MTVA Stock Forecast: MetaVia, Inc. Price Predictions for 2026-2027

Last close, 13 Nov 2026

$1.27

−2.69% on the day

The 2 Wall Street analysts covering MetaVia, Inc. hold a median 12-month price target of $20 — +1481.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 13 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$8.6M

Ticker Nerd rank

17/ 100

Median analyst target

$20

Analysts covering

Revenue$0.0

Operating income−$5.4M

Net income−$5.3M

Free cash flow−$3.8M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−11.5%

YTD

−85.0%

−82.6%

From 52W high

−89.0%

From 52W low

+30.4%

$12

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

MTVA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MetaVia, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Nov 2026

17/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Growth

Accruals

Revisions

Volatility

Quality

Momentum

Issuance

Value

Size (92): Smaller than most of the companies we track.

Value (9): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MTVA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MTVA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts

2 Buy0 Hold0 Sell

Low $8Median $20High $30

The green dot is the last close — the median target sits +1481.0% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
10 July 2026	HC Wainwright & Co.	Reiterates	Buy	$20
18 May 2026	HC Wainwright & Co.	Reiterates	Buy	—
27 Mar 2026	HC Wainwright & Co.	Maintains	Buy	—
6 Jan 2026	HC Wainwright & Co.	Maintains	Buy	—
4 Sept 2025	HC Wainwright & Co.	Assumes	Buy	$12
19 May 2025	Maxim Group	Maintains	Buy	—
16 Apr 2025	HC Wainwright & Co.	Reiterates	Buy	—
21 Mar 2025	HC Wainwright & Co.	Reiterates	Buy	—
30 Dec 2024	HC Wainwright & Co.	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MTVA appears in the Radar on the weeks it earns a place.

Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

The AI build-out map

PDF

AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST

Performance

MTVA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Nov 2026, MetaVia, Inc. returned −82.6% against +13.4% for the S&P 500, dividends included.

MTVA vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MTVA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year

Analysts raising

Analysts cutting

Fundamentals

MetaVia, Inc. (MTVA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.2×
Price / sales: —
Price / book: 1.3×
EV / EBITDA: 0.3×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −175.7%
Return on assets: −58.8%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

MetaVia, Inc. (MTVA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

MetaVia, Inc. has a market value of $8.6M and an enterprise value of −$3.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$14.4M.
Free cash flow in the twelve months to 30 June 2026: −$15.8M.
Shares outstanding: 5.2M.
Trailing P/E: −0.2×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
MetaVia, Inc. employs 8 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Nov 2026

Data provided by Twelve Data

Peers

MTVA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
MTVAMetaVia, Inc.	$8.6M	17
INABIN8bio, Inc.	$8.9M	31
MBRXMoleculin Biotech, Inc.	$8.3M	21
CALCCalciMedica, Inc.	$8.3M	37
PHIOPhio Pharmaceuticals Corp.	$9.0M	28
ENSCEnsysce Biosciences, Inc.	$8.1M	34
AEONAEON Biopharma, Inc.	$9.0M	45

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MetaVia, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MTVA news & analysis

MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update

PRNewsWire · 13 Nov 2026positive

MetaVia reported positive interim 16-week Phase 1 Part 3 data for DA-1726 that support planned Phase 2 development in MetALD and ALD. The company appointed Sarah Browne, M.D., as chief medical officer and expects full Phase 1 Parts 3A and 3B data in the first quarter of 2027.

Why it matters — The update outlines the next planned development stage for DA-1726 and a leadership appointment relevant to MetaVia’s clinical programs.

MetaVia's Potential Drug Candidate Cuts Serum Uric Acid and Liver Fat

Benzinga · 12 Nov 2026positive

MetaVia announced additional interim results from Part 3B of its Phase 1 clinical trial of DA-1726. The headline reports reductions in serum uric acid and liver fat.

Why it matters — The update provides information for MTVA watchers on interim findings from the company’s clinical-stage drug candidate.

MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026

PRNewsWire · 9 Nov 2026positive

MetaVia announced that an abstract on DA-1726 has been accepted for a poster presentation at ObesityWeek 2026, scheduled for November 14–17 in Washington, DC. DA-1726 is described as a dual OXM analog targeting GLP-1 and glucagon receptors.

Why it matters — The presentation will feature information about MetaVia’s clinical-stage DA-1726 program at an obesity-focused conference.

MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data

PRNewsWire · 5 Nov 2026positive

MetaVia reported interim Phase 1 Part 3B data for DA-1726, including a statistically significant 68% reduction in liver fat, 13.5% placebo-adjusted weight loss, and a reduction in mean HbA1c among participants without diabetes. The company reported no new gastrointestinal adverse events after Week 9 through Day 109 and said full Part 3A and 3B data are expected in the first quarter of 2027.

Why it matters — The findings support the planned 48-week, non-biopsy Phase 2 study of DA-1726 in patients with MetALD and ALD, targeted to begin in the second half of 2027.

MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026

PRNewsWire · 28 Oct 2026positive

MetaVia announced that an abstract highlighting Phase 1 clinical trial data for DA-1726 was accepted for an oral presentation at the Precision Liver Symposium 2026, scheduled for November 4 in Denver.

Why it matters — The presentation will provide an opportunity for investors to learn about Phase 1 data for MetaVia’s investigational DA-1726 program.

FAQ

Frequently asked questions about MTVA stock

What is the MTVA stock price forecast for 2026-2027?

The 2 Wall Street analysts covering MetaVia, Inc. have a median 12-month price target of $20, with estimates ranging from $8 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MTVA stock a buy right now?

Of the 2 analysts covering MetaVia, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MetaVia, Inc. 17 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MTVA?

As at 13 Nov 2026, MetaVia, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

Will MTVA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +1481.0% from the last close, and Ticker Nerd's factor model ranks MetaVia, Inc. 17 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MTVA stock forecast for 2030?

No analyst covering MetaVia, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MTVA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $30 over the next 12 months.

How has MTVA stock performed over the past year?

MetaVia, Inc. returned -82.6% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MetaVia, Inc. do?

MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cardiometabolic diseases.

What is the latest news on MTVA?

The most recent item we track (PRNewsWire, 13 Nov 2026): "MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update". MetaVia reported positive interim 16-week Phase 1 Part 3 data for DA-1726 that support planned Phase 2 development in MetALD and ALD. The company appointed Sarah Browne, M.D., as chief medical officer and expects full Phase 1 Parts 3A and 3B data in the first quarter of 2027.

Company

About MetaVia, Inc.

MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel therapies for cardiometabolic diseases. The company’s current programs center on obesity and metabolic dysfunction-associated steatohepatitis (MASH), with an emphasis on drug candidates designed to address metabolic regulation, appetite control, and related disease pathways. MetaVia’s pipeline also includes research in type 2 diabetes and other cardiometabolic conditions, reflecting its broader focus on diseases linked to metabolic dysfunction. Based in Cambridge, Massachusetts, MetaVia operates in the biopharmaceutical sector, where its role is to advance early- and mid-stage drug development through clinical testing and therapeutic innovation.

CEO Mr. Hyung Heon Kim · 8 employees · United States · https://www.metaviatx.com